J T Siveke1, C Folwaczny. 1. II. Medizinische Klinik, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
Abstract
BACKGROUND: Immunosuppressive therapy employing purine analogues is the therapeutic mainstay in patients with chronic active ulcerative colitis. However, despite therapeutic optimization according to thiopurine-methyltransferase activity or red blood cell 6-thioguanine levels, a substantial proportion of patients does not tolerate azathioprine or 6-mercaptopurine or relapses during this treatment. In the latter multiple therapeutic regimens comprising 6-thioguanine, cyclosporin or tacrolimus, methotrexate, cyclophosphamide, infliximab, interferons, heparin, leukocyte apheresis, and various other regimens might be considered aiming at long-term remission. Many of these treatment forms have only been evaluated in small mostly uncontrolled trials. OBJECTIVE: In this review existing treatment modalities and future options for patients with chronic active ulcerative colitis will be discussed focusing on immunomodulating approaches.
BACKGROUND: Immunosuppressive therapy employing purine analogues is the therapeutic mainstay in patients with chronic active ulcerative colitis. However, despite therapeutic optimization according to thiopurine-methyltransferase activity or red blood cell 6-thioguanine levels, a substantial proportion of patients does not tolerate azathioprine or 6-mercaptopurine or relapses during this treatment. In the latter multiple therapeutic regimens comprising 6-thioguanine, cyclosporin or tacrolimus, methotrexate, cyclophosphamide, infliximab, interferons, heparin, leukocyte apheresis, and various other regimens might be considered aiming at long-term remission. Many of these treatment forms have only been evaluated in small mostly uncontrolled trials. OBJECTIVE: In this review existing treatment modalities and future options for patients with chronic active ulcerative colitis will be discussed focusing on immunomodulating approaches.
Authors: K Fellermann; M Steffen; J Stein; A Raedler; J Hämling; D Ludwig; K Loeschke; E F Stange Journal: Aliment Pharmacol Ther Date: 2000-02 Impact factor: 8.171
Authors: S M Madsen; P Schlichting; B Davidsen; O H Nielsen; B Federspiel; P Riis; P Munkholm Journal: Am J Gastroenterol Date: 2001-06 Impact factor: 10.864
Authors: V Muratov; J Lundahl; A K Ulfgren; K Elvin; I Fehrman; N Ahlborg; A Ost; N Hittel; A Saniabadi; R Löfberg Journal: Int J Colorectal Dis Date: 2006-03-15 Impact factor: 2.571